AMRX:NYE-Amneal Pharmaceuticals Inc. Class A Common Stock (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5.87

Change

-0.03 (-0.51)%

Market Cap

USD 1.82B

Volume

0.96M

Analyst Target

USD 4.11
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.21 (+1.95%)

USD 66.94B
TAK Takeda Pharmaceutical Co Ltd A..

+0.31 (+2.37%)

USD 41.54B
HLN Haleon plc

+0.07 (+0.85%)

USD 37.53B
TEVA Teva Pharma Industries Ltd ADR

+0.26 (+1.65%)

USD 15.80B
RDY Dr. Reddy’s Laboratories Ltd..

-2.04 (-2.85%)

USD 11.85B
CTLT Catalent Inc

-0.22 (-0.39%)

USD 10.04B
ELAN Elanco Animal Health

+0.31 (+1.84%)

USD 6.40B
PRGO Perrigo Company PLC

-0.09 (-0.29%)

USD 4.11B
PBH Prestige Brand Holdings Inc

+0.47 (+0.67%)

USD 3.47B
EVT Eaton Vance Tax Advantaged Div..

+0.15 (+0.64%)

USD 3.26B

ETFs Containing AMRX

LNGG Roundhill Alerian LNG ETF 12.32 % 0.00 %

+0.37 (+0%)

USD 0.74M
MVR:AU VanEck Vectors Australian.. 6.34 % 0.00 %

-1.23 (0%)

USD 0.43B
ROYA 5.61 % 0.00 %

N/A

N/A
QRE:AU Beta Shares S&P/ASX 200Re.. 4.61 % 0.00 %

-0.04 (0%)

USD 0.21B
OZR:AU SPDR S&P/ASX 200 Resource.. 4.29 % 0.00 %

-0.08 (0%)

USD 0.17B
SYI:AU SPDR MSCI Australia Selec.. 3.39 % 0.00 %

-0.21 (0%)

USD 0.45B
IAPD:SW iShares Asia Pacific Divi.. 3.12 % 0.00 %

N/A

USD 0.40B
OAEM OneAscent Emerging Market.. 3.11 % 0.00 %

+0.03 (+0%)

USD 0.05B
IDAP:LSE iShares Asia Pacific Divi.. 3.05 % 0.00 %

+0.06 (+0%)

USD 0.40B
IAPD:LSE iShares Asia Pacific Divi.. 2.98 % 0.00 %

+3.00 (+0%)

USD 0.40B
MVW:AU VanEck Vectors Australian.. 1.38 % 0.00 %

-0.19 (0%)

USD 2.27B
DLS WisdomTree International .. 0.71 % 0.58 %

+0.50 (+0%)

USD 1.10B
DVYA iShares Asia/Pacific Divi.. 0.00 % 0.49 %

+0.21 (+0%)

USD 0.04B
EXXW:F iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

N/A

USD 0.30B
IQQX:F iShares Public Limited Co.. 0.00 % 0.00 %

-0.02 (0%)

USD 0.40B
EXXW:XETRA iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

+0.02 (+0%)

USD 0.29B
IQQX:XETRA iShares Asia Pacific Divi.. 0.00 % 0.00 %

+0.01 (+0%)

USD 0.40B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.29% 47% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.29% 47% F 25% F
Trailing 12 Months  
Capital Gain 204.15% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 204.15% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -52.78% 38% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.78% 38% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain 20.10% 100% F 84% B
Dividend Return 20.10% 100% F 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.53% 12% F 10% F
Risk Adjusted Return 25.27% 71% C- 48% F
Market Capitalization 1.82B 35% F 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.